Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

Blood

Volumn 114, Issue 10, 2009, Pages 2037-2043

  Jabbour, Elias ^a   Jones, Daniel ^a   Kantarjian, Hagop M ^a   O'Brien, Susan ^a   Tam, Constantine ^a   Koller, Charles ^a   Burger, Jan A ^a   Borthakur, Gautam ^a   Wierda, William G ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOGENETICS; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; GENE MUTATION; HUMAN; IN VITRO STUDY; LONG TERM CARE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DOMAIN; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; AGE; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENETICS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MORTALITY; MUTATION; PROTEIN TERTIARY STRUCTURE; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SPAIN; SURVIVAL RATE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HOSPITALS, PUBLIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIFE EXPECTANCY; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RETROSPECTIVE STUDIES; SPAIN; SURVIVAL RATE; THIAZOLES;

EID: 70349245253     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-197715     Document Type: Article

References (45)

1. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007;1092(6):2171-2181. (Pubitemid 46801546)
2. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645-652. (Pubitemid 34815868)
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. (Pubitemid 36302244)
4. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11(9):3425-3432. (Pubitemid 40627896)
5. Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate vs interferon- α-based regimens in newly diagnosed chronicphase chronic myelogenous leukemia. Blood. 2006;108(6):1835-1840. (Pubitemid 44394991)
6. Hochhaus A, Druker B, Larson RA, et al. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood. 2007;110(11):15a.
7. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005;183-187.
8. Hochhaus A, Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am. 2004;18(3):641-656. (Pubitemid 38969136)
9. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006; 20(10):1767-1773. (Pubitemid 44574988)
10. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276-283. (Pubitemid 36759665)
11. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol. 2005; 23(18):4100-4109. (Pubitemid 46211315)
12. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004;11(1):35-43. (Pubitemid 38021719)
13. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7(2):129-141. (Pubitemid 40248339)
14. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401. (Pubitemid 38938156)
15. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-4505. (Pubitemid 40740783)
16. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med. 2006;354(24): 2531-2541. (Pubitemid 43882349)
17. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome- positive ALL. N Engl J Med. 2006; 354(24):2542-2551. (Pubitemid 43882350)
18. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-1820. (Pubitemid 44394987)
19. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645-652. (Pubitemid 34815868)
20. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110(7):2242-2249. (Pubitemid 47523141)
21. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib, dasatinib (BMS-354825), and nilotinib (AMN107) in an n-ethyl-n-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108(7):2332-2338. (Pubitemid 44497517)
22. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of Bcr/Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (Nilotinib) by a random mutagenesis study. Blood. 2007;109(11):5011-5015. (Pubitemid 46827801)
23. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood. 2006; 108(4):1328-1333. (Pubitemid 44232032)
24. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A. 2005;102(9): 3395-3400.
25. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27(3):469-471.
26. Snedecor G, Cochran W. Statistical Methods. 7th ed. Ames, IA: Iowa State University; 1980.
27. Kaplan EL, Maier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1965;53:457-481.
28. Agresti A. Categorical Data Analysis. 2nd ed. Hoboken, NJ: John Wiley & Sons; 1990.
29. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
30. Kantarjian HM, Giles F, Bhalla KN, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood. 2008;112(11):Abstract 3238.
31. Baccarani M, Rosti G, Saglio G, et al. Dasatinib: time and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood. 2008;112(11):Abstract 450.
32. Guilhot F, Apperley JF, Kin D-W, et al. Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005) [abstract]. Blood. 2007; 110(11):Abstract 470.
33. le Coutre P, Giles FJ, Hochhaus A, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up, results of a phase 2 study [abstract]. Blood. 2008;112(11):Abstract 3229.
34. Gambacorti C, Cortes J, Kim D-W, et al. Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program [abstract]. Blood. 2007;110(11):Abstract 472.
35. Giles FJ, le Coutre P, Bhalla KN, et al. Efficacy and tolerability of nilotinib in chronic myeloid leukemia in chronic phase (CML-CP) who failed prior imatinib and dasatinib therapy: updated results of a phase 2 study [abstract]. Blood. 2008;112(11): Abstract 3234.
36. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP). J Clin Oncol. In press.
37. Saglio G, Kim DW, Hochhaus A, et al. Correlation of clinical response to nilotinib with BCR-ABL mutation status in advanced phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or intolerance [abstract]. Blood. 2007; 110(11):Abstract 1940.
38. Muller MC, Cortes J, Kim DW, et al. Dasatinib efficacy in patients with chronic myelogenous leukemia in chronic phase (CML-CP) and preexisting BCR-ABL mutations [abstract]. Blood. 2008;112(11):Abstract 449.
39. Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110(12):4005-4011. (Pubitemid 350248456)
40. Soverini S, Martinelli G, Colarossi S, et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol. 2006;24(33):51-52.
41. Jabbour E, Kantarjian HM, Jones D, et al. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008; 112(13):4839-4842.
42. Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007;109(2):497-499. (Pubitemid 46105944)
43. Giles F, le Coutre P, Bhalla K, et al. Nilotinib (Tasigna7® ) therapy after dasatinib failure in patients with imatinib-resistant or -intolerant Ph+ CP-, AP- and BC-CML. Blood. 2007;110(11):Abstract 1029.
44. Jabbour E, Kantarjian H, Jones D, et al. In vivo response to sequential tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) modeled based on in vitro properties of particular BC-RABL kinase domain (KD) mutations. Blood. 2007; 110(11):Abstract 1045.
45. Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009;16(2):122-131.